Literature DB >> 1856488

Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh.

D A Sack1, J D Clemens, S Huda, J R Harris, M R Khan, J Chakraborty, M Yunus, J Gomes, O Siddique, F Ahmed.   

Abstract

Sera collected during the 1985 oral cholera vaccine trial in Matlab, Bangladesh, which demonstrated efficacy of a whole cell combined with cholera B subunit vaccine (WC/BS) and a whole cell only vaccine (WC), were analyzed for antitoxin and vibriocidal antibodies. Before vaccines were given, antitoxin titers were highest in children, especially those with O blood group, whereas vibriocidal titers rose throughout life. Two weeks after three doses of vaccine, geometric mean antitoxin titers were 2.5-4.5 times higher in vaccinees who received the WC/BS vaccine; the vibriocidal titers were 1.3-2.1 times higher in vaccinees who received either vaccine. The titer elevations were relatively brief and were barely detectable 7 months after the third dose even though significant levels of protection persisted greater than or equal to 3 years. Thus, the oral vaccines induced a serum response in this large field trial that was similar to that seen in earlier pilot studies, but the duration of the serum responses was much shorter than the duration of the protection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1856488     DOI: 10.1093/infdis/164.2.407

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh.

Authors:  Daniel T Leung; Mohammad Arif Rahman; M Mohasin; Sweta M Patel; Amena Aktar; Farhana Khanam; Taher Uddin; M Asrafuzzaman Riyadh; Amit Saha; Mohammad Murshid Alam; Fahima Chowdhury; Ashraful Islam Khan; Richelle Charles; Regina LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

2.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.

Authors:  R K Gupta; S C Szu; R A Finkelstein; J B Robbins
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

3.  Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.

Authors:  Wilbur H Chen; Richard N Greenberg; Marcela F Pasetti; Sofie Livio; Michael Lock; Marc Gurwith; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

4.  Validation of a volunteer model of cholera with frozen bacteria as the challenge.

Authors:  D A Sack; C O Tacket; M B Cohen; R B Sack; G A Losonsky; J Shimko; J P Nataro; R Edelman; M M Levine; R A Giannella; G Schiff; D Lang
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

5.  Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers.

Authors:  D A Sack; J Shimko; R B Sack; J G Gomes; K MacLeod; D O'Sullivan; D Spriggs
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

Review 6.  Immunology of gut mucosal vaccines.

Authors:  Marcela F Pasetti; Jakub K Simon; Marcelo B Sztein; Myron M Levine
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 7.  Immune responses to cholera in children.

Authors:  Daniel T Leung; Fahima Chowdhury; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Expert Rev Anti Infect Ther       Date:  2012-04       Impact factor: 5.091

Review 8.  Critical analysis of compositions and protective efficacies of oral killed cholera vaccines.

Authors:  Shahjahan Kabir
Journal:  Clin Vaccine Immunol       Date:  2014-07-23

9.  Spatial and environmental connectivity analysis in a cholera vaccine trial.

Authors:  Michael Emch; Mohammad Ali; Elisabeth D Root; Mohammad Yunus
Journal:  Soc Sci Med       Date:  2009-01-08       Impact factor: 4.634

10.  Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.

Authors:  R Lagos; A Avendaño; V Prado; I Horwitz; S Wasserman; G Losonsky; S Cryz; J B Kaper; M M Levine
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.